丙戊酸镁联合抗精神病药治疗精神分裂症攻击行为

Combination of magnesium valproate and anti-psychotics in aggressive behaviors of schizophrenics

目的 评价丙戊酸镁联合抗精神病药治疗精神分裂症患者攻击行为的疗效。方法 将60例有攻击行为的精神分裂 症住院患者随机分为研究组30例,对照组30例。研究组在原有抗精神病药治疗的同时加用丙戊酸镁治疗,起始剂量400mg ·d-1,1w后增至800mg～1200mg·d-1;对照组继续原有抗精神病药治疗。疗程4w。两组于治疗前及治疗第4w末采用简 明精神病评定量表、治疗前及治疗第1、2、4w末采用外显攻击行为量表、副反应量表评定疗效与不良反应。结果 两组治疗前 与治疗后简明精神病评定量表各因子分差异均有极显著性(P<0.01);治疗后两组间比较差异无显著性(P>0.05);两组治疗 前后外显攻击行为量表评分有极显著性差异(P<0.01),治疗第2、4w末两组间比较有极显著性差异(P<0.01),研究组评分 降低更为明显。结论 在常规应用抗精神病药治疗精神分裂症的攻击行为时,加服丙戊酸镁疗效更佳。

Objective To assessed the curative effects of the combination of magnesium valproate and anti-psychotics in the treatment of aggressive behaviors of schizophrenics. Methods Sixty inpatient schizophrenics with aggressive behaviors were randomly divided into research and control groups(each n=30). Research group were given anti-psychotics combined with magnesium valproate, its beginning dosage was 400mg/d and reached 800~1200mg/d after one week, and control group with single anti-psychotics for 4 weeks. All patients were assessed with Brief Psychiatric Rating Scale(BPRS), Modified Overt Aggression Scale (MOAS) and Treatment Emergent Symptoms Scale(TESS). Results There were significant difference in factor's scores of BPRS between pre- and post-treatment of the both 2 groups(P<0.0), and no difference between the 2 groups after treatment(P>0.05); there was significant difference in the score of the MOAS between pre-and post-treatment of both the 2 groups(P<0.01) and between the 2 groups at the ends of 2 nd and 4 th week(P<0.01). Scores of research group were significantly lower than that of control group. Conclusion Combination of magnesium valproate and anti-psychotics is the best in the treatment of aggressive behaviors of schizophrenics.